Enhanced oral bioavailability of EGCG using pH-sensitive polymeric nanoparticles: characterization and in vivo investigation on nephrotic syndrome rats
机构：[1]Department of Nephrology, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China临床科室肾内科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, People’s Republic of China
Objective: Chronic kidney disease (CKD) is characterized by progressive loss of renal functions. At present, there are only limited therapeutic strategies to slow down the progress of CKD and there is an urgent need to develop new therapeutic strategies to treat CKD patients. Numerous research evidence supports the potential role of EGCG in the renal protection of CKD. However, the clinical use is still limited due to the poor oral bioavailability. The aim of this study was to develop pH-sensitive polymeric nanoparticles of EGCG to improve this deficiency. Materials and methods: EGCG-loaded nanoparticles (EGCG NPs) were prepared by an improved emulsion evaporation method. The formulation prepared was in spherical with uniform sizes, high encapsulation efficiencies and drug loading. The therapeutic efficacy of EGCG NPs on chronic kidney disease was investigated on model of rat Nephrotic syndrome by measuring urinary protein excretion and kidney pathology score. Results: Thu mean particle size was found to be 91.3 +/- 0.8 nm and the encapsulation efficiency% and drug loading% of the formulation were 80.8%+/- 1.6% and 6.3%+/- 1.4%, respectively. The powder X-ray diffraction and differential scanning calorimetry of EGCG NPs showed that EGCG existed in amorphous form in NPs. The release of EGCG from NPs exhibited the lower burst release at pH 1.2 (<10%) and with the increase of pH value, the release of EGCG also gradually increased. During the observation period (24 hours), the total release amount was almost 68%. EGCG NPs could significantly modify the pharmacokinetic profile and increase the bioavailability of EGCG by more than 2.4-fold in comparison with the EGCG powder group. At the end of the fourth and sixth week, proteinuria excretion of nephrotic syndrome rats treated with EGCG NPs was significantly lower than those treated with EGCG powder, and kidney pathology scores in EGCG NPs treated rats were also significantly lower than EGCG powder treated rats. Conclusion: The results of pharmacodynamics showed that compared with EGCG powder treatment group, EGCG NPs treatment group had better efficacy and reduce kidney damage.
第一作者机构：[1]Department of Nephrology, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China[*1]Department of Nephrology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, People’s Republic of China
通讯作者：
通讯机构：[1]Department of Nephrology, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China[*1]Department of Nephrology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, People’s Republic of China
推荐引用方式(GB/T 7714)：
Zhang Guojuan,Zhang Jianfang.Enhanced oral bioavailability of EGCG using pH-sensitive polymeric nanoparticles: characterization and in vivo investigation on nephrotic syndrome rats[J].DRUG DESIGN DEVELOPMENT AND THERAPY.2018,12:2509-2518.doi:10.2147/DDDT.S172919.
APA：
Zhang, Guojuan&Zhang, Jianfang.(2018).Enhanced oral bioavailability of EGCG using pH-sensitive polymeric nanoparticles: characterization and in vivo investigation on nephrotic syndrome rats.DRUG DESIGN DEVELOPMENT AND THERAPY,12,
MLA：
Zhang, Guojuan,et al."Enhanced oral bioavailability of EGCG using pH-sensitive polymeric nanoparticles: characterization and in vivo investigation on nephrotic syndrome rats".DRUG DESIGN DEVELOPMENT AND THERAPY 12.(2018):2509-2518
